NAD+ laboratory research at Youth Lab Peptides

The 8-week “long-term” study

The title promises long-term administration. The NR trial ran for 8 weeks in healthy overweight adults. Its studied groups received 100, 300 or 1000 milligrams daily, and whole-blood NAD+ rose by 22%, 51% and 142%, respectively. These describe study exposures, with no personal dosing implication.

No significant difference in adverse events emerged against placebo, and the researchers reported no flushing. That orderly blood response impresses me. I’m much less ready to let “long-term” expand from the experiment’s window to a lifetime of use. The result establishes a biochemical response during that period; the rest requires follow-up.

NR means nicotinamide riboside. Along with NMN, nicotinamide mononucleotide, it is a precursor: material cells can use to make NAD+. Most controlled human evidence concerns these oral precursors. Direct NAD+ infusions take another route and have much less controlled evidence.

NMN functional findings

The 60-day NMN trial in healthy middle-aged adults measured walking distance and ratings of health as well as blood NAD+. Walking and quality-of-life scores improved compared with placebo. The trial was randomized and blinded, with participants and staff unaware of treatment assignment. That makes the functional observations worth pursuing.

In postmenopausal women with prediabetes, a 10-week NMN trial improved muscle insulin sensitivity. In other words, muscle responded better to the signal that helps take sugar out of blood. Body composition and HbA1c, a longer-term blood-sugar measure, did not change.

Those are two different kinds of progress, in different populations. I favor the walking result and the specified muscle response over the blood concentration alone. A convincing next chapter would follow those changes into ordinary life.

How secure is the age-related decline?

I expected the basic shortage story to be tidier. The 2025 review of human NAD+ precursor research says consistent age-related decline has appeared in only a limited number of human studies, while measurements within particular tissues remain sparse. Blood is accessible. A particular muscle or organ is harder to sample, and its supply is a different question.

The biology is substantial. NAD+ helps cells release energy from food and supports enzymes involved in DNA repair and signaling, as the review of NAD+ metabolism during aging describes. In mice lacking the NAD-consuming enzyme CD38, NAD+ levels were preserved with age and mitochondrial function improved. Mitochondria are the cell structures that help generate usable energy. Those results came from mice.

The heart-failure work combined human heart tissue with a mouse model. Restoring NAD+ improved cardiac function in the mice through a specific metabolic pathway. It was no clinical trial demonstrating that NAD+ treatment improved heart failure in people. The experiment earns its own interest without borrowing that outcome.

Oral precursors, infusions and safety

The NMN study and NR study provide reassuring short-term tolerability findings for their oral study preparations. Their scope leaves years of exposure and direct NAD+ injection safety unsettled. NAD+ itself breaks down before most cells can take it up intact; delivery into blood bypasses digestion without supplying the missing clinical outcomes.

The safety record also includes nausea, flushing and chest or abdominal discomfort when intravenous NAD+ is delivered too quickly. A separate endotoxin recall carried FDA’s Class I designation and concerned a compounded injection. Endotoxin is harmful material from bacteria: a preparation-quality problem distinct from a result about NAD+ metabolism.

Existing cancer is another unresolved context because cancer cells also use NAD+. A concern about supporting their metabolism is mechanistic reasoning, not a demonstrated human cancer effect of supplementation. FDA has disputed NMN’s eligibility for the dietary-supplement category; that legal dispute establishes no health benefit. Neither supplement use nor wellness infusion has FDA approval to treat a specific illness.

Give me the material actually studied: oral NR, oral NMN or direct NAD+. The BPC-157 vs NAD+ comparison explains why separate findings cannot establish a benefit from using them together.